Aktuelle und künftige Indikationen mit Bendamustin: chronische lymphatische Leukämie, indolente Lymphome, Mantelzell-Lymphome und diffuse großzellige B-Zell-Lymphome

Publisher: Karger

E-ISSN: 2296-5262|36|1|11-18

ISSN: 2296-5270

Source: Oncology Research and Treatment, Vol.36, Iss.1, 2013-01, pp. : 11-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next